Replies to post #247479 on Avid Bioservices Inc (CDMO)

[jbainseky]

Obviously there is confusion, something changed, or Shan made a mistake somewhere because in May 2015 he stated:

As a reminder, SUNRISE is designed as a Phase III registration trial and has two planned interim analyses. The first is purely to assess safety and the second will assess both safety and efficacy. As the interim analyses are triggered and a certain number of trial events are reached, in this case depths, we cannot at this point guide to when these might occur.

At least according to BioBS2012 in post of the transcript via Post 210742

FFTT

JBAIN